Inhibiting oncogenic kinases to target metabolism in AML

抑制致癌激酶以靶向 AML 代谢

• 批准号: 265305
• 负责人: Schimmer Aaron D
• 金额: $ 52.04万
• 依托单位: Princess Margaret Cancer Centre (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-09-01 至 2017-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=265305&lang=en
• 关键词: Cell Biology; Kinases; Leukemia; Metabolism; Rnai

Acute myeloid leukemia (AML) is an aggressive blood cancer. The majority of patients with AML still die from their disease and therapy for this condition is essentially unchanged in the last 20 years. Even though we have learned more about the genetic a

急性髓性白血病（AML）是一种侵袭性血癌。在过去的20年里，大多数AML患者仍然死于他们的疾病，治疗这种疾病的方法基本上没有改变。尽管我们对基因有了更多的了解